Q-omics provides the consensus-scored SUCLG2 profile across patient tissues and cancer cell-line models. SUCLG2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUCLG2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SUCLG2 RNA expression shows 20,059 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SUCLG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUCLG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUCLG2 survival associations across molecular data types. SUCLG2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUCLG2 RNA expression–survival associations across cancer types. High SUCLG2 expression shows unfavorable associations in LUAD, SCLC, LAML and BLCA, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUCLG2 RNA expression.
This table summarizes SUCLG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUCLG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUCLG2 shows lower tumor expression in COAD, KIRC, HNSC, KIRP, LUSC and THCA. The COAD box plot shows higher SUCLG2 RNA expression in normal versus tumor tissue (log2 FC = −1.734, t-test p < 0.001).
This table shows molecular features associated with SUCLG2 in patient tissues and cancer cell lines. In patient samples, SUCLG2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUCLG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
